Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12


See accompanying editorial doi: 10.1200/JCO.2014.56.6802

ABSTRACT

Purpose
For patients with relapsed or refractory aggressive lymphoma, we hypothesized that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as effective as and less toxic than standard treatment.

Patients and Methods
We randomly assigned 619 patients with relapsed/refractory aggressive lymphoma to treatment with gemcitabine, dexamethasone, and cisplatin (GDP) or to dexamethasone, cytarabine, and cisplatin (DHAP). Patients with B-cell lymphoma also received rituximab. Responding patients proceeded to stem-cell collection and ASCT. Coprimary end points were response rate after two treatment cycles and transplantation rate. The noninferiority margin for the response rate to GDP relative to DHAP was set at 10%. Secondary end points included event-free and overall survival, treatment toxicity, and quality of life.

Results
For the intention-to-treat population, the response rate with GDP was 45.2%; with DHAP the response rate was 44.0% (95% CI for difference, −9.0% to 6.7%), meeting protocol-defined criteria for noninferiority of GDP (P = .005). Similar results were obtained in a per-protocol analysis. The transplantation rates were 52.1% with GDP and 49.3% with DHAP (P = .44). At a median follow-up of 53 months, no differences were detected in event-free survival (HR, 0.99; stratified log-rank P = .95) or overall survival (HR, 1.03; P = .78) between GDP and DHAP. Treatment with GDP was associated with less toxicity (P < .001) and need for hospitalization (P < .001), and preserved quality of life (P = .04).

Conclusion
For patients with relapsed or refractory aggressive lymphoma, in comparison with DHAP, treatment with GDP is associated with a noninferior response rate, similar transplantation rate, event-free survival, and overall survival, less toxicity and hospitalization, and superior quality of life.

J Clin Oncol 32. © 2014 by American Society of Clinical Oncology
and did not interfere with the ability to collect peripheral blood stem cells. We thus hypothesized that treatment with GDP before high-dose chemotherapy and ASCT would be as effective and associated with less morbidity compared with DHAP.

**PATIENTS AND METHODS**

**Study Oversight**

The NCIC Clinical Trials Group (CTG) LY.12 study was a randomized controlled trial conducted in 26 Canadian centers, 10 American centers, and one Australian center, and, in collaboration with the Gruppo Italiano Studio Linfomi (GISL), 18 centers in Italy. We designed this trial to compare GDP with DHAP as second-line chemotherapy before ASCT (first random assignment) and to evaluate the efficacy of post-transplantation treatment with the anti-CD20 antibody rituximab (second random assignment). The results of the first random assignment are the subject of this report. The LY.12 protocol was designed by the NCIC CTG Lymphoma Committee. The trial was approved by the research ethics boards of all participating centers, and written informed consent was provided by all participants. An independent data and safety monitoring committee monitored the trial at confidential meetings every 6 months and evaluated data that were provided at the two interim analyses. The NCIC CTG office in Kingston, Ontario, Canada, was responsible for data management and statistical analysis. The NCIC CTG conducted this trial with financial support obtained with a grant from the Canadian Cancer Society Research Institute. Financial support and supply of gemcitabine were provided by Eli Lilly; rituximab was provided by Roche Canada. The trial was independently designed, conducted, and analyzed by the NCIC CTG.

**Treatment Protocol**

Eligible patients were age 18 years or older, with aggressive-histology lymphoma according to the WHO classification. The histologic diagnosis, including determination of T- or B-cell lineage by immunohistochemistry, was documented by biopsy before initial therapy or at relapse and confirmed by a local reference pathologist. Patients with diffuse large B-cell lymphoma (DLBCL, including variants), peripheral T-cell lymphoma, and anaplastic large-cell lymphoma were required to have received previous treatment with one anthracycline-containing chemotherapy regimen. Patients with DLBCL arising from a background of follicular or other indolent-histology lymphoma

**Fig 1.** CONSORT diagram for NCIC Clinical Trials Group study LY.12. The intention-to-treat population (ITT) included all randomly assigned patients. The per-protocol (as treated) population (PPP) included all eligible patients who received at least one cycle of assigned protocol therapy. ASCT, autologous stem-cell transplantation; DHAP, dexamethasone, cytarabine, and cisplatin; GDP, gemcitabine, dexamethasone, and cisplatin.

Completed ASCT after clinical cutoff date (n = 1)

Discontinued protocol treatment (n = 127) before ASCT

Died (n = 6)
Progressive disease (n = 87)
Insufficient response (n = 18)
Intercurrent illness (n = 1)
Toxicity (n = 9)
Received more than three cycles of chemotherapy (n = 3)
Patient refusal (n = 1)
Lost to follow-up (n = 1)

Discontinued protocol treatment (n = 112) before ASCT

Died (n = 4)
Progressive disease (n = 78)
Insufficient response (n = 17)
Intercurrent illness (n = 2)
Toxicity (n = 5)
Received more than three cycles of chemotherapy (n = 3)
Patient refusal (n = 3)

Discontinued protocol treatment (n = 127) before ASCT

Died (n = 6)
Progressive disease (n = 87)
Insufficient response (n = 18)
Intercurrent illness (n = 1)
Toxicity (n = 9)
Received more than three cycles of chemotherapy (n = 3)
Patient refusal (n = 1)
Lost to follow-up (n = 1)

Completed ASCT after clinical cutoff date (n = 1)

Discontinued protocol treatment (n = 112) before ASCT

Died (n = 4)
Progressive disease (n = 78)
Insufficient response (n = 17)
Intercurrent illness (n = 2)
Toxicity (n = 5)
Received more than three cycles of chemotherapy (n = 3)
Patient refusal (n = 3)

Discontinued protocol treatment (n = 127) before ASCT

Died (n = 6)
Progressive disease (n = 87)
Insufficient response (n = 18)
Intercurrent illness (n = 1)
Toxicity (n = 9)
Received more than three cycles of chemotherapy (n = 3)
Patient refusal (n = 1)
Lost to follow-up (n = 1)

Completed ASCT after clinical cutoff date (n = 1)

Discontinued protocol treatment (n = 112) before ASCT

Died (n = 4)
Progressive disease (n = 78)
Insufficient response (n = 17)
Intercurrent illness (n = 2)
Toxicity (n = 5)
Received more than three cycles of chemotherapy (n = 3)
Patient refusal (n = 3)

Discontinued protocol treatment (n = 127) before ASCT

Died (n = 6)
Progressive disease (n = 87)
Insufficient response (n = 18)
Intercurrent illness (n = 1)
Toxicity (n = 9)
Received more than three cycles of chemotherapy (n = 3)
Patient refusal (n = 1)
Lost to follow-up (n = 1)

Completed ASCT after clinical cutoff date (n = 1)
were eligible provided that they had received no more than three previous treatment regimens, with at least one regimen including an anthracycline. Baseline assessments included physical examination, standard laboratory testing, computed tomography (CT) scanning of the chest, abdomen, and pelvis, bone marrow biopsy, and, if indicated, CSF analysis (Data Supplement). Eligible patients were required to have measurable disease by CT scan or physical examination, an Eastern Cooperative Oncology Group performance status6 of 0 to 3, and acceptable hematologic and biochemical parameters. Patients were excluded if they had previously received treatment with cisplatin, cytarabine, or gemcitabine; had CNS involvement with lymphoma, history of HIV infection, or a medical condition that would interfere with the safe delivery of the protocol chemotherapy.

Patients were stratified by treating center, International Prognostic Index7 risk factors at trial entry, immunophenotype (B cell v T cell), response to primary therapy (refractory, relapse at ≤ 1 year, or relapse at > 1 year) and previous rituximab treatment, and a concealed random assignment process8 using a computer-generated minimization procedure was performed to allocate patients with equal probabilities to the experimental (GDP) or control (DHAP) group. Two cycles of protocol therapy were administered at 21-day intervals and consisted of either intravenous gemcitabine 1,000 mg/m² of body surface area per day on days 1 and 8 and cisplatin 75 mg/m² on day 1, and oral dexamethasone 40 mg per day on days 1 through 4 (GDP); or oral dexamethasone 40 mg per day on days 1 through 4 and intravenous cytarabine 2 g/m² over 3 hours once every 12 hours for two doses on day 2 and cisplatin 100 mg/m² by 24-hour continuous infusion on day 1 (DHAP). Patients who had not achieved a complete or partial response after two treatment cycles were permitted to receive a third cycle of protocol therapy. The study was amended in November 2005 to provide patients with CD20+ lymphoma treatment with rituximab 375 mg/m² intravenously on day 1 of each treatment cycle before the administration of chemotherapy. Treatment with GDP was designed to be delivered to patients in an outpatient setting and included a recommended minimum hydration schedule for cisplatin.9 Dose attenuations for treatment-related toxicity were prescribed (Data Supplement). Patients with a positive test for hepatitis B surface antigen were recommended to be monitored for hepatitis B reactivation and to receive lamivudine. Primary prophylaxis against febrile neutropenia with granulocyte colony-stimulating factor was not mandated.

Each participating center was responsible for determining policies for hematopoietic stem-cell mobilization, choice of high-dose chemotherapy regimen, supportive care after stem-cell reinfusion, and use of post-transplantation involved-field radiation to areas of bulky disease at relapse or progression.

**Assessment of Response and Definition of Study Outcomes**

Patients underwent disease re-evaluation after two and, if applicable, three cycles of protocol therapy. Imaging tests to evaluate remission status were repeated 3, 7, 13, and 25 months after stem-cell reinfusion and when clinically indicated. Response assessment was categorized according to the 1999 International Working Group criteria.10 Patients receiving a nonprotocol salvage chemotherapy regimen that was different from that allocated by random assignment were categorized as having an event and withdrawn from the study. The primary end point of response rate by arm after two cycles of treatment was calculated by considering the number of patients achieving a complete, unconfirmed complete, or partial response among those randomly assigned (intent-to-treat analysis) and among those eligible patients who received at least one cycle of protocol therapy (per-protocol analysis). An additional, post hoc, per-protocol analysis was performed that also excluded patients who were alive and without documented disease progression who were not evaluated after two cycles of treatment. The transplantation rate by arm was calculated by considering the number of patients categorized as achieving a response to therapy and meeting criteria for successful stem-cell mobilization (obtaining at least 2 × 10⁶ CD34+ cells/kg of body weight) among those receiving at least one cycle of assigned chemotherapy; a sensitivity analysis was performed that included all randomly assigned patients. Overall survival was calculated from the date of random assignment to date of death from any cause; event-free survival was calculated from the date of random assignment to the date of objective or symptomatic disease progression, relapse after objective response, initiation of new lymphoma therapy, or death from any cause. Event-free and overall survivals were evaluated using data from an intention-to-treat population. Adverse events were graded according to National Cancer Institute Common Toxicity Criteria version 2.0.11 Quality of life (QoL) was measured using the Functional Assessment of Cancer Therapy (FACT) instrument,12 including a subscale for neurologic toxicity and a lymphoma-specific subscale,12 and was assessed at baseline, end of cycle 1, middle and end of cycle 2, and 1 month after stem-cell infusion. A change in a QoL item rating of 10% or more when compared with the baseline value was considered a clinically meaningful change.

**Statistical Analysis**

The primary objective associated with the first random assignment of the LYC trial was to test whether the response rate obtained after two cycles of GDP was noninferior to the response rate obtained with DHAP. If GDP was shown to be noninferior, the transplantation rates of GDP and DHAP would be evaluated for superiority of GDP. Secondary objectives included comparing GDP and DHAP with respect to event-free and overall survival, rates of successful stem-cell mobilization, frequency of adverse events, QoL, and resource usage. Assuming that the response rate obtained would be 50% with DHAP and 60% with DHAP-rituximab, GDP would be considered noninferior if the one-sided upper 95% confidence limit for the difference in response

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>GDP (n = 310)</th>
<th>DHAP (n = 309)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median Range</td>
<td>55.2</td>
<td>54.6</td>
</tr>
<tr>
<td>&gt; 60</td>
<td>88</td>
<td>89</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>122</td>
<td>118</td>
</tr>
<tr>
<td>Male</td>
<td>188</td>
<td>191</td>
</tr>
<tr>
<td>ECOG performance status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>127</td>
<td>130</td>
</tr>
<tr>
<td>1</td>
<td>141</td>
<td>137</td>
</tr>
<tr>
<td>≥ 2</td>
<td>42</td>
<td>42</td>
</tr>
<tr>
<td>Disease stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>79</td>
<td>76</td>
</tr>
<tr>
<td>IV</td>
<td>138</td>
<td>134</td>
</tr>
<tr>
<td>Immunophenotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>277</td>
<td>277</td>
</tr>
<tr>
<td>Tnull/NK</td>
<td>33</td>
<td>32</td>
</tr>
<tr>
<td>Histology, lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse large B cell</td>
<td>216</td>
<td>203</td>
</tr>
<tr>
<td>Transformed indolent</td>
<td>42</td>
<td>45</td>
</tr>
<tr>
<td>Peripheral T cell</td>
<td>12</td>
<td>15</td>
</tr>
<tr>
<td>Anaplastic large cell</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>Primary mediastinal</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>IPI risk factors at entry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0, 1</td>
<td>115</td>
<td>117</td>
</tr>
<tr>
<td>2</td>
<td>88</td>
<td>89</td>
</tr>
<tr>
<td>≥ 3</td>
<td>100</td>
<td>98</td>
</tr>
<tr>
<td>Response to previous treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete response</td>
<td>81</td>
<td>83</td>
</tr>
<tr>
<td>Complete response &lt; 1 year</td>
<td>129</td>
<td>128</td>
</tr>
<tr>
<td>No response/progressive disease</td>
<td>95</td>
<td>94</td>
</tr>
<tr>
<td>Previous therapy including</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiation</td>
<td>76</td>
<td>73</td>
</tr>
<tr>
<td>Rituximab</td>
<td>205</td>
<td>205</td>
</tr>
</tbody>
</table>

Abbreviations: DHAP, dexamethasone, cytarabine, cisplatin; ECOG, Eastern Cooperative Oncology Group; GDP, gemcitabine, dexamethasone, cisplatin; IPI, International Prognostic Index; NK, natural killer.
rate between the two arms was less than 10%. To exclude a 10% difference with 80% power, 630 eligible patients were required. An interim analysis for futility around the noninferiority end point was planned after 320 patients were enrolled; the protocol was amended to add a second interim analysis after 480 patients were entered, resulting in a final sample size of 637 patients.

The chi-squared test was used to compare the rates of response, transplantation, adverse events, and successful stem-cell mobilization of the two treatment arms. The Kaplan and Meier\(^{14}\) life-table method was used to calculate event-adverse events, and successful stem-cell mobilization of the two treatment arms. This was approved in November 2011.

The request was submitted to the data safety monitoring committee to allow an additional year of accrual would be needed to meet the planned sample size. A (SAS Institute, Cary, NC).

In October 2011, the trial committee recognized that more than 1 additional year of accrual would be needed to meet the planned sample size. A request was submitted to the safety monitoring committee to allow closure of accrual; this was approved in November 2011.

**RESULTS**

**Patients**

From August 2003 to November 2011, we randomly assigned 619 patients. Seven patients were subsequently considered to be ineligible, and seven did not receive therapy according to their allocation; these 14 patients were equally distributed between the two arms (Fig 1). The median age of the patients was 55 years, and 28% were older than age 60 years. Most patients had stage III or IV and high-intermediate or high-risk disease\(^{7}\) at random assignment, and had either not achieved a remission with initial therapy or had recurrence of lymphoma within 1 year of completing treatment. Seventy-one percent had DLBCL, 15% had lymphoma that had transformed from an indolent B-cell histology; 8% had T-cell or anaplastic large-cell lymphoma. Among 554 patients with B-cell lymphoma, 411 had received rituximab as part of previous therapy (Table 1).

**Treatment Outcomes**

At least two cycles of protocol therapy were received by 90% of patients who were allocated to the GDP group (277 of 306 patients) and 87% of those who were allocated to the DHAP group (266 of 304 patients). In the intention-to-treat population, the rate of response after two cycles of treatment was 45.1% in the GDP group and 44.1% in the DHAP group (\(P = .84\)). The upper boundary of the one-sided 95.6% CI for the difference in response rates was 5.7%, thus meeting the protocol-specified criterion for noninferiority of GDP compared with DHAP (\(P = .005\)). The primary and post hoc per-protocol analyses also met criteria for noninferiority (Table 2). The transplantation rate was 52.1% in the GDP group and 49.3% in the DHAP group (difference between arms [DHAP – GDP], –2.5%; 95% CI, –10.5% to 5.5%; \(P = .44\)). Similar results were observed among the intention-to-treat population. The rate of successful stem-cell mobilization (defined as collection of > 2.0 × 10\(^6\) CD34\(^+\) cells/kg) was 87.9% in the GDP group and 82.2% in the DHAP group (\(P = .14\)). Thirty-three patients treated with GDP and 26 patients receiving DHAP who were planned for transplantation on the basis of response to protocol therapy did not proceed to ASCT because of disease progression (GDP arm, 19 patients; DHAP arm, 13 patients) or inability to collect stem cells (GDP arm, six patients; DHAP arm, seven patients; Fig 1).

The median duration of follow-up was 53 months. No differences were detected in the 4-year event-free survival (HR, 0.99; 95% CI, 0.82 to 1.21; stratified log-rank \(P = .95\); Fig 2A) or overall survival (HR, 1.03; 95% CI, 0.83 to 1.28; \(P = .78\)) of the GDP and DHAP groups, respectively (Fig 2B).

**Table 2. Treatment Outcomes According to Intention-to-Treat, Primary, and Sensitivity Per-Protocol Analyses**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>GDP</th>
<th></th>
<th>DHAP</th>
<th></th>
<th>Difference (DHAP – GDP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate of response (CR, CRu, PR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intention-to-treat population†</td>
<td>140 of 310</td>
<td>136 of 309</td>
<td>.005†</td>
<td>–1.2</td>
<td>–9.0 to 6.7</td>
</tr>
<tr>
<td>Overall RR</td>
<td>46.1</td>
<td>44.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR/CRu</td>
<td>13.5</td>
<td>14.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>31.6</td>
<td>29.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary per-protocol analysis‡</td>
<td>140 of 303</td>
<td>135 of 302</td>
<td>.004‡</td>
<td>–1.5</td>
<td>–9.4 to 6.4</td>
</tr>
<tr>
<td>Overall RR</td>
<td>46.1</td>
<td>44.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR/CRu</td>
<td>13.8</td>
<td>14.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>32.3</td>
<td>30.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity per-protocol analysis§</td>
<td>140 of 287</td>
<td>135 of 284</td>
<td>.004‡</td>
<td>–1.3</td>
<td>–9.4 to 7.0</td>
</tr>
<tr>
<td>Rate of transplantation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intention-to-treatment analysis†</td>
<td>158 of 310</td>
<td>151 of 309</td>
<td>.59‡</td>
<td>–2.1</td>
<td>–10.0 to 5.8</td>
</tr>
<tr>
<td>Per-protocol analysis§</td>
<td>158 of 303</td>
<td>149 of 302</td>
<td>.44‡</td>
<td>–2.5</td>
<td>–10.5 to 5.5</td>
</tr>
</tbody>
</table>

Abbreviations: CR, complete response; CRu, complete response unconfirmed; DHAP, dexamethasone, cytarabine, cisplatin; GDP, gemcitabine, dexamethasone, cisplatin; PR, partial response; RR, response rate.

†Includes four patients assessed after one cycle who had durable responses (two PRs, one CRu, one CR).

‡Based on 619 patients who were randomly assigned.

§For noninferiority.

¶For superiority.

*Based on 405 eligible patients who received at least one dose of assigned therapy.

†Based on 571 eligible patients who received at least one dose of assigned therapy and were evaluable for response.
Patients with aggressive lymphoma and disease progression or recurrence after primary chemotherapy experience superior overall survival when treated with high-dose chemotherapy and ASCT compared with continued treatment with standard doses of chemotherapy. Several second-line chemotherapy regimens that are designed to increase the proportion of patients eligible for transplantation through the use of more intense chemotherapy have been evaluated and are associated with substantial hematologic toxicity and considerable use of health care resources. At the time we initiated our study, no randomized trials comparing salvage chemotherapy regimens had been conducted. We tested the hypothesis that comparable efficacy could be achieved with GDP and that this treatment, administered on an outpatient basis, would be associated with fewer adverse events and less frequent hospitalization compared with DHAP.

Our trial is the largest randomized comparison of second-line chemotherapy regimens administered before autologous stem-cell transplantation, to our knowledge, and the results confirmed our hypothesis. We observed that the overall rate of response that was obtained with GDP was noninferior to DHAP and that GDP was associated with fewer grade 3 and 4 adverse events, including febrile neutropenia, less frequent need for hospitalization related to toxicity, reduced need for platelet transfusion support, and better preservation of patient-reported QoL. Having met the primary end point of the trial, we also assessed whether a greater number of patients would...
proceed to transplantation if treated with GDP. Although this end point was not met, the proportions of patients achieving a stem-cell collection of $>2.0 \times 10^6$ CD34+ peripheral blood stem cells/kg (87.9% v 82.2%) and proceeding to autologous transplantation (52.1% v 49.3%) seem to be similar with GDP and DHAP, respectively. Finally, no differences were detected in 4-year event-free (26% in each group) or overall survivals (39% in each group).

We chose response to therapy as the primary end point for this study because sensitivity to chemotherapy is a fundamental prerequisite for proceeding to autologous transplantation. The response rate we observed seems to be less than that reported by Gisselbrecht et al,2 who compared rituximab plus DHAP with rituximab, ifosfamide, carboplatin, and etoposide. Eligibility for that trial was restricted to patients with DLBCL, whereas our study included patients with transformed indolent lymphoma and T-cell lymphoma. In addition, more than 70% of patients in our study either did not achieve a remission with primary therapy or experienced recurrence within 1 year of completing that therapy, factors that predict for a lower rate of response and poorer event-free survival.19 Nonetheless, the proportion of patients proceeding to transplantation in both studies was similar, as was overall survival after 3 years of follow-up.20 The proportion of patients event-free 4 years after transplantation was 53% in the study by Gisselbrecht et al,21 which is similar to that observed in the current study (43% for GDP and 49% for DHAP; Data Supplement).

Outcomes after ASCT for patients with aggressive lymphoma have consistently been shown to be related to clinical variables that include International Prognostic Index risk factors,22 and previous exposure to the CD20 antibody rituximab,20,23 in addition to histology and previous response duration. Recently, it has been recognized that germinal center B-cell and activated B-cell subtypes of DLBCL, defined by gene expression profiling, have distinct molecular origins and natural histories, which may also account for variability in outcomes after ASCT.24 An exploratory analysis by Thieblemont et al25 of immunohistochemical and molecular profiling of biopsies from patients who experienced relapse suggests that response to different salvage regimens may not be uniform between these subtypes of aggressive lymphoma, providing a potential avenue, if confirmed, for selective addition of agents that target these genetic differences. We are currently analyzing biopsy samples from patients who were enrolled onto our trial to determine if cell of origin and other molecular biomarkers are correlated with response and long-term outcomes.

In summary, for patients with relapsed or refractory aggressive-histology lymphoma, treatment with GDP before high-dose chemotherapy and ASCT is as effective as DHAP and is associated with fewer adverse events, less frequent need for hospitalization, and superior patient-reported QoL. This treatment can be considered the preferred treatment option for these patients.

Fig 3. (A) Mean change in total Functional Assessment of Cancer Therapy–General (FACT-G) scores; significant differences were seen at the end of cycle 1 (End 1), the middle of cycle 2 (Mid 2), and the end of cycle 2 (End 2). (B) Percentage of patients reporting a minimally important difference in FACT-G total score of 10% or more, assessed at midpoint of cycle 2: more patients who received gemcitabine, dexamethasone, and cisplatin (GDP) experienced improvement in and fewer experienced deterioration in quality of life than those treated with dexamethasone, cytarabine, and cisplatin (DHAP). ASCT, autologous stem-cell transplantation.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) and/or an author’s immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None Consultant or Advisory Role: David A. MacDonald, Roche Canada (C); Ralph M. Meyer, Eli Lilly (C) Stock Ownership: None Honoraria: John Kuruvilla, Roche Canada; David A. MacDonald, Roche Canada; Tara Baetz, Roche Research Funding: Michael Crump, Roche Canada; John Kuruvilla, Roche Canada; David A. MacDonald, Roche Canada Expert Testimony: None Patents, Royalties, and Licenses: None Other Remuneration: None

AUTHOR CONTRIBUTIONS

REFERENCES


Appendix

List of Participating Countries, Groups, Centers, and Investigators